Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3684 | Revefenacin (YUPELRI) & Formoterol (Perforomist) Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.09 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
D055371 | Acute Lung Injury NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.
Description: This is a scale asks the subject to rate the difficulty of their breathing. It starts at number 0 where breathing is causing no difficulty at all and progresses through to number 10 where breathing difficulty is maximal. This will be recorded prior to dosing twice a day between 7 and 9 am & pm. Scores from Group 1 and Group 2 will be averaged and compared.
Measure: Difference in Borg Dyspnea Scale scores between groups Time: change from baseline borg dyspnea score at day 3Description: This is a scale asks the subject to rate the difficulty of their breathing. It starts at number 0 where breathing is causing no difficulty at all and progresses through to number 10 where breathing difficulty is maximal. This will be recorded prior to dosing twice a day between 7 and 9 am & pm. Scores from Group 1 and Group 2 will be averaged and compared.
Measure: Difference in Borg Dyspnea Scale scores between groups Time: change from baseline borg dyspnea score at day 7Description: This is a scale asks the subject to rate the difficulty of their breathing. It starts at number 0 where breathing is causing no difficulty at all and progresses through to number 10 where breathing difficulty is maximal. This will be recorded prior to dosing twice a day between 7 and 9 am & pm. Scores from Group 1 and Group 2 will be averaged and compared.
Measure: Difference in Borg Dyspnea Scale scores between groups Time: change from day 3 borg dyspnea score at day 7Description: Subject in both groups will be allowed to use standard of care rescue short-acting bronchodilators throughout their study participation.
Measure: Difference in the mean total doses of short acting bronchodilators (rescue) used during study participation between each group. Time: up to 7 daysDescription: The lowest level of FiO2 will be recorded from the subjects EMR record at each visit during study participation and the difference between group 1 and group 2 will be noted.
Measure: The difference in the lowest level of FiO2 employed at each visit between group 1 and group 2 Time: at baselineDescription: The lowest level of FiO2 will be recorded from the subjects EMR record at each visit during study participation and the difference between group 1 and group 2 will be noted.
Measure: The difference in the lowest level of FiO2 employed at each visit between group 1 and group 2 Time: at day 3Description: The lowest level of FiO2 will be recorded from the subjects EMR record at each visit during study participation and the difference between group 1 and group 2 will be noted.
Measure: The difference in the lowest level of FiO2 employed at each visit between group 1 and group 2 Time: at day 7Description: Total percent of patients that had to switch therapy due to lack of response between each group.
Measure: Number of total subjects that had to stop treatment early between groups Time: Through study completion, up to 7 daysDescription: Adverse Events, SAE's, ET, and Deaths will be recorder for every subjects in both groups until the end of their study participation.
Measure: The total number of subjects with Adverse Events, SAE's, ET, and Deaths between groups. Time: Through study completion, up to 7 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports